Assignee
EPIC SCIENCES INC
US·3 granted patents·28 pending applications·6 citations·filing 2015–2024
Top patents by PatentIndex Score
31 records- 0181US10545151B2Methods for analyzing rare circulating cellsEPIC SCIENCES INC·Filed 2015·Granted Jan 28, 2020·2 cites·18 claims
- 0277US10527624B2Circulating tumor cell diagnostics for prostate cancer biomarkersEPIC SCIENCES INC·Filed 2015·Granted Jan 7, 2020·4 cites·14 claims
- 0377US2025180564A1Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneityEPIC SCIENCES INC·Filed 2024·Application pending·0 cites
- 0472US2024319193A1Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapiesEPIC SCIENCES INC·Filed 2023·Application pending·0 cites
- 0571US2025130236A1Methods for the detection and quantification of circulating tumor cell mimicsEPIC SCIENCES INC·Filed 2024·Application pending·0 cites
- 0669US11340228B2Methods for analyzing rare circulating cellsEPIC SCIENCES INC·Filed 2019·Granted May 24, 2022·0 cites·39 claims
- 0768US2024103003A1Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)EPIC SCIENCES INC·Filed 2023·Application pending·0 cites
- 0868US2025155440A1Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic diseaseEPIC SCIENCES INC·Filed 2024·Application pending·0 cites
- 0964US2022390451A1Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneityEPIC SCIENCES INC·Filed 2022·Application pending·0 cites
- 1063US2021405055A1Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneityEPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 1163US2024036047A1ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)EPIC SCIENCES INC·Filed 2023·Application pending·0 cites
- 1262US2022091124A1Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapiesEPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 1362US2022162706A1Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc)EPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 1459US2023033449A1Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)EPIC SCIENCES INC·Filed 2022·Application pending·0 cites
- 1558US2021382057A1Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)EPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 1658US2021373026A1Methods for the detection and quantification of circulating tumor cell mimicsEPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 1756US2022091123A1Circulating tumor cell diagnostics for identification of resistance to androgen receptor targeted therapiesEPIC SCIENCES INC·Filed 2021·Application pending·0 cites
- 1854US2020333345A1Circulating tumor cell diagnostics for prostate cancer biomarkersEPIC SCIENCES INC·Filed 2019·Application pending·0 cites
- 1954US2023175073A1Enhanced characterization of breast cancerEPIC SCIENCES INC·Filed 2022·Application pending·0 cites
- 2053US2018321247A1Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneityEPIC SCIENCES INC·Filed 2016·Application pending·0 cites
- 2151US2018052167A1Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapiesEPIC SCIENCES INC·Filed 2017·Application pending·0 cites
- 2249US2019025312A1Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneityEPIC SCIENCES INC·Filed 2017·Application pending·0 cites
- 2348US2022260574A1Methods of determining therapies based on single cell characterization of circulating tumor cells (ctcs) in metastatic diseaseEPIC SCIENCES INC·Filed 2018·Application pending·0 cites
- 2448US2018155794A1Intra-patient genomic heterogeneity of single circulating tumor cells (ctcs) associated to phenotypic ctc heterogeneity in metastatic castrate resistant prostate cancer (mcrpc)EPIC SCIENCES INC·Filed 2016·Application pending·0 cites
- 2546US2015212089A1Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapiesEPIC SCIENCES INC·Filed 2015·Application pending·0 cites
- 2644US2016011198A1Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc)EPIC SCIENCES INC·Filed 2015·Application pending·0 cites
- 2744US2016341732A1Methods for the detection and quantification of circulating tumor cell mimicsEPIC SCIENCES INC·Filed 2015·Application pending·0 cites
- 2843US2019285636A1ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC)EPIC SCIENCES INC·Filed 2016·Application pending·0 cites
- 2941US2017285035A1Circulating tumor cell diagnostics for identification of resistance to androgen receptor targeted therapiesEPIC SCIENCES INC·Filed 2015·Application pending·0 cites
- 3040US2016040245A1Circulating tumor cell diagnostics for detection of neuroendocrine prostate cancer (nepc)EPIC SCIENCES INC·Filed 2015·Application pending·0 cites
- 3126US2017242016A1Circulating tumor cell diagnostics for therapy targeting pd-l1EPIC SCIENCES INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when EPIC SCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →